SWEETNAM PAUL enters RETENSION PHARMACEUTICALS, INC. with 402.58K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 10/8/2026ACC: 0001213900-26-108140
Officer· Chief Scientific Officer
Since Oct 2026
402.58K
Baseline shares
100% direct
402.58K
Direct ownership
1 position
216.01K
Derivative underlying
4 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Stock
DirectShares owned402.58K
Total
402.58K direct402.58K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 402.58K | Direct |
| Total | 402.58K | 402.58K direct |
Derivative Holdings4
Stock Option (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
80.52K
Shares owned
N/A
Exercise price
1.43
Expiration
—
Exercise window
—
Series A Convertible Preferred Stock
DirectUnderlying security
Common Stock
Underlying shares
4.03K
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Series B Convertible Preferred Stock
IndirectUnderlying security
Common Stock
Underlying shares
2.64K
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Stock Option (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
128.82K
Shares owned
N/A
Exercise price
2.43
Expiration
—
Exercise window
—
Total
Underlying
216.01K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock | 1.43 | — | — | 80.52K | N/A |
| Series A Convertible Preferred Stock Direct | Common Stock | — | — | 4.03K | N/A | |
| Series B Convertible Preferred Stock Indirect | Common Stock | — | — | 2.64K | N/A | |
| Stock Option (right to buy) Direct | Common Stock | 2.43 | — | — | 128.82K | N/A |
| Total | 216.01K | 0.00 | ||||